Efficacy

Portrazza (Necitumumab) Efficacy in Lung Cancer

Portrazza (necitumumab) is a monoclonal antibody designed for the treatment of advanced squamous non-small cell lung cancer (NSCLC). It targets the epidermal growth factor receptor (EGFR), which is often overexpressed in squamous NSCLC cells. The efficacy of Portrazza was evaluated in a clinical trial that included patients with advanced squamous NSCLC who had not received prior chemotherapy for their advanced disease. In this trial, Portrazza, in combination with chemotherapy, showed a statistically significant improvement in overall survival compared to chemotherapy alone. Patients treated with Portrazza plus chemotherapy had a median survival of 11.5 months compared to 9.9 months for those who received chemotherapy alone.

However, it is important to note that Portrazza is not indicated for patients with non-squamous NSCLC. Its efficacy has been specifically demonstrated in the squamous subgroup of NSCLC, which is a distinction that healthcare providers must consider when choosing a treatment regimen for their patients with lung cancer.

Keytruda (Pembrolizumab) Efficacy in Lung Cancer

Keytruda (pembrolizumab) is a highly effective immunotherapy drug used in the treatment of various types of cancer, including lung cancer. For NSCLC, Keytruda's efficacy has been demonstrated in several clinical trials. It works by targeting the programmed death receptor-1 (PD-1) pathway, thereby enhancing the body's immune response against cancer cells. In patients with metastatic NSCLC whose tumors express PD-L1, Keytruda has been shown to significantly improve overall survival rates compared to traditional chemotherapy. The improvement in survival was particularly notable in patients with high PD-L1 expression.

Keytruda has also been approved for use as a first-line treatment in certain patients with metastatic NSCLC. In this setting, it has been shown to improve progression-free survival as well as overall survival when compared to standard chemotherapy regimens. The efficacy of Keytruda has established it as a standard of care in the first-line treatment of PD-L1 positive NSCLC, changing the treatment landscape for this disease. As with all treatments, the efficacy of Keytruda can vary based on individual patient factors, including the level of PD-L1 expression and the presence of specific genetic mutations.